nanomaterials-logo

Journal Browser

Journal Browser

New Progress in Targeted Delivery of Nanocarriers

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: closed (15 May 2026) | Viewed by 1552

Special Issue Editor


E-Mail Website1 Website2
Guest Editor
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, Campus Universitario de Cartuja s/n, 18071 Granada, Spain
Interests: active drug targeting; biomedical applications of colloids and nanoparticles; biopharmacy; drug absorption; drug delivery; drug release; formulation and evaluation of pharmaceutical dosage forms; hyperthermia-based anticancer treatment; in vivo fate of nanoplatforms; ligand-receptor interactions and nanoparticle endocytosis; long-circulating nanoparticles; magnetic colloids; nanoteranosis; passive drug targeting; PEGylated nanoparticles; pharmaceutical technology; pharmacokinetics; stimuli sensitive nanostructures; surface chemistry and interface science; surface functionalization of nanoparticles
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Targeted therapies based on multifunctional nanoparticles have generated promising results in optimized efficacy and reduced collateral toxicity. However, engineering nanoparticulate systems continue to encounter technical problems in vitro, e.g., reproducibility, the appropriate loading of active agents, or colloidal stability, to name only a few. Furthermore, biological barriers represent important walls interfering with their successful in vivo fate. The blood–brain barrier, pleural fluid, and mucins on mucous membranes are among the most relevant barricades limiting the targeted delivery of nanomedicines. Recently, there has been significant progress in optimizing the therapeutic efficacy of these nanomaterials.

This Special Issue of Nanomaterials hopes to receive contributions (in the form of research articles, letters, reviews, and communications) that provide an update on the applications and perspectives associated with the engineering of therapeutically efficient nanomedicines. In addition, this special issue will analyze the barriers to drug delivery and provide an overview of the various approaches employed to address related topics.

I kindly invite you to contribute to this Special Issue of Nanomaterials entitled “New Progress in Targeted Delivery of Nanocarriers”.

Prof. Dr. Jose L. Arias
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • passive drug targeting
  • active drug targeting
  • nanoparticles
  • ligand-mediated delivery
  • image-guided drug delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 6238 KB  
Article
Brain-Targeted Delivery of Phenformin Using Phospholipid and Non-Phospholipid Vesicles for SHH Medulloblastoma
by Laura Di Magno, Federica Rinaldi, Luca Campea, Giorgia Della Rocca, Jacopo Forte, Eleonora D’Intino, Sara Cairoli, Bianca Maria Goffredo, Maria Carafa, Elena Del Favero, Carlotta Marianecci and Gianluca Canettieri
Nanomaterials 2026, 16(9), 566; https://doi.org/10.3390/nano16090566 - 4 May 2026
Viewed by 1003
Abstract
Medulloblastoma (MB) is the most frequent brain malignancy in children, frequently driven by deregulated Sonic Hedgehog (SHH) signaling. We previously identified the antidiabetic drug phenformin (Phen) as a potent Gli1 inhibitor that suppresses SHH-subtype MB growth. Despite its efficacy, systemic administration of Phen [...] Read more.
Medulloblastoma (MB) is the most frequent brain malignancy in children, frequently driven by deregulated Sonic Hedgehog (SHH) signaling. We previously identified the antidiabetic drug phenformin (Phen) as a potent Gli1 inhibitor that suppresses SHH-subtype MB growth. Despite its efficacy, systemic administration of Phen is limited by its potential to induce lactic acidosis, primarily through the suppression of hepatic gluconeogenesis. Here, we provide proof-of-concept that phospholipid (liposomes) and non-phospholipid (niosomes) vesicles (<200 nm) can be used to deliver phenformin selectively. Our results show that these vesicle-based delivery systems efficiently entrap Phen (around 50%) and release it into SHH MB cells, reducing proliferation and activating energy stress responses at higher doses. Furthermore, treated cells exhibit marked downregulation of SHH target genes Gli1 and Ptch1. In vivo, phenformin-loaded nanocarriers selectively increased drug accumulation in cerebellar tumors while minimizing systemic and hepatic exposure. Notably, niosomes demonstrated superior brain tumor targeting compared to free drug or liposome administration, as reflected by higher intratumoral concentrations of Phen compared to free drug or liposome administration. Consistent with this targeted delivery, we observed a substantial decline in intratumoral Gli1 and Ptch1 expression, confirming effective SHH pathway modulation. Together, these findings propose a promising nanotechnology-based method to improve phenformin therapeutic index in SHH MB by enhancing tumor specificity and reducing systemic toxicity. Full article
(This article belongs to the Special Issue New Progress in Targeted Delivery of Nanocarriers)
Show Figures

Graphical abstract

Back to TopTop